| scholarly article | Q13442814 |
| P356 | DOI | 10.1101/SQB.1994.059.01.053 |
| P698 | PubMed publication ID | 7587102 |
| P50 | author | Michael Tainsky | Q67482970 |
| P2093 | author name string | N Bouck | |
| O V Volpert | |||
| K M Dameron | |||
| P304 | page(s) | 483-489 | |
| P577 | publication date | 1994-01-01 | |
| P1433 | published in | Cold Spring Harbor Symposia on Quantitative Biology | Q15758412 |
| P1476 | title | The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin | |
| P478 | volume | 59 |
| Q37402504 | A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. |
| Q36166483 | Angiogenesis inhibitors found within the haemostasis pathway. |
| Q35104246 | Anti-angiogenic agents for the treatment of brain tumors |
| Q93353440 | Antiangiogenic Gene Therapy in Cancer |
| Q37386616 | Armed replicating adenoviruses for cancer virotherapy |
| Q39246000 | Autocrine stimulation of clear-cell renal carcinoma cell migration in hypoxia via HIF-independent suppression of thrombospondin-1. |
| Q77099561 | BRCA1 carries tumor suppressor activity distinct from that of p53 and p21 |
| Q36465291 | Breast tumour angiogenesis |
| Q35081097 | Cancer gene therapy |
| Q34572090 | Cancer gene therapy: fringe or cutting edge? |
| Q33776331 | Contribution of p53 to metastasis |
| Q38347516 | DNA binding specificity of proteins derived from alternatively spliced mouse p53 mRNAs |
| Q35800448 | Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy |
| Q26827810 | Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. |
| Q91800352 | Extracellular Matrix Degradation Products Downregulate Neoplastic Esophageal Cell Phenotype |
| Q41100541 | How tumors become angiogenic |
| Q24314623 | Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane |
| Q36206830 | Influence of TP53 Codon 72 Polymorphism Alone or in Combination with HDM2 SNP309 on Human Infertility and IVF Outcome |
| Q36105141 | Inhibition of tumor angiogenesis and growth by nanoparticle-mediated p53 gene therapy in mice |
| Q36859052 | Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. |
| Q35809398 | MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas |
| Q37962472 | Modulation of angiogenesis by dietary phytoconstituents in the prevention and intervention of breast cancer |
| Q34178900 | Molecular mechanisms of tumor angiogenesis and tumor progression |
| Q30354662 | Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers. |
| Q73763323 | Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth |
| Q53693166 | Oncosuppressors and Oncogenes: Role in Haemangioma Genesis and Potential for Therapeutic Targeting. |
| Q53424015 | Opponents of stem-cell patent win restrictions. |
| Q34241518 | P53 in bladder cancer: mechanism of action, prognostic value, and target for therapy |
| Q37143062 | PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway |
| Q35936830 | Prognostic value of VEGF in human pancreatic ductal adenocarcinoma |
| Q54505940 | Recurrent pregnancy failure is associated with a polymorphism in the p53 tumour suppressor gene. |
| Q82993549 | Role of p53 codon 72 polymorphism in recurrent pregnancy loss |
| Q35668936 | Roles of main pro- and anti-angiogenic factors in tumor angiogenesis |
| Q35567287 | Strategies for reversing drug resistance |
| Q35133764 | Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. |
| Q35750446 | Synthetic retinoids as inducers of apoptosis in ovarian carcinoma cell lines |
| Q91643844 | Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors |
| Q36600928 | The history of the angiogenic switch concept |
| Q40930917 | The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. |
| Q33851136 | The potential role of gene therapy in the treatment of bladder cancer |
| Q35681952 | The proline TP53 variant stimulates likely lymphangiogenesis in an orthotopic mouse model of pancreatic cancer |
| Q39532585 | The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo |
| Q38974266 | Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action. |
| Q77359737 | Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate |
| Q43592018 | Thymidine phosphorylase expression causes both the increase of intratumoral microvessels and decrease of apoptosis in human esophageal carcinomas |
| Q54579010 | p53 tumour suppressor gene polymorphism is associated with recurrent implantation failure. |
| Q45888635 | p53: balancing tumour suppression and implications for the clinic |
| Q92932823 | pVHL-mediated regulation of the anti-angiogenic protein thrombospondin-1 decreases migration of Clear Cell Renal Carcinoma Cell Lines |
Search more.